- Patrys (PAB) claims a recent pre-clinical study of its PAT-DX3 drug shows the product could treat cancer through “synthetic lethality” strategies
- The company says its drug platform is designed to cause DNA damage to certain tumours to ultimately kill cancer cells while having little impact on normal cells
- According to Patrys, a recent colon cancer study in mice treated with PAT-DX3 shows that tumours with this type of DNA damage showed a 71 per cent reduction in growth — more than double the 35 per cent growth reduction in other tumours
- PAB CEO and Managing Director James Campbell says this study shows the potential of the company’s product to treat cancers with pre-existing mutations that compromise their DNA damage response systems
- PAB shares are up 4.17 per cent and trading at 2.5 cents at 2:16 pm AEDT
Patrys (PAB) has claimed a recent pre-clinical study of its PAT-DX3 drug showed the product could treat cancer through “synthetic lethality” strategies.
PAB’s drug platform is designed to cause DNA damage while having little impact on normal cells.
In tumours with pre-existing mutations that compromise their DNA damage response (DDR) systems, this additional inhibition from Patrys’ deoxymab products could cause enough damage to kill the tumour cells — a process known as synthetic lethality.
PAB conducted a pre-clinical colon cancer animal study in mice treated with PAT-DX3. The company said tumours with a compromise DDR system showed a 71 per cent reduction in growth — more than double the 35 per cent growth reduction in other tumours.
The company said this response rate provided further evidence of a synthetic lethality mode of action for Patrys’ deoxymab products — a first for therapeutic antibodies.
“This is an exciting and important result that shows, for the first time, the comparative effects of a Patrys deoxymab on tumours with or without DDR mutations in the same animal,” PAB CEO and Managing Director James Campbell said.
“This study confirms the potential to use deoxymabs as a single agent to treat
cancers that have pre-existing mutations that compromise their DDR systems, including
BRCA2 negative breast cancer and other cancers,” Dr Campbell said.
PAB’s mouse study also confirmed that all tumours in animals treated with PAT-DX3 displayed an accumulation of DNA damage.
The level of DNA damage was significantly higher in DDR-deficient tumours.
PAB shares were up 4.17 per cent and trading at 2.5 cents at 2:16 pm AEDT.